Alzamend Neuro, Inc.

Stage 2 · Advancing · week 4

As of Oct 22, 2026, Alzamend Neuro is in Stage 2, the uptrend phase, now in week 4 (since Sep 28, 2026). It closed at $1.12, 57.1% below its 52-week high and below its 200-day average, which is falling.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. More about the company

$1.12

-10.51% today

$5.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ALZN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S4 81w

S4 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 30w → S1 5w → S4 81w → S1 3w → S4 31w → S1 13w → S2 4w current

Total tracked: 166 weeks across 7 stage runs.

ALZN among Biotechnology370th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…370	ALZNAlzamend Neuro, Inc.	Stage 2 · wk 4	22	−42.3%

vs 52W High

-57.1%

$0.86 lo$2.61 hi

57.1% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-25.9%

200 DMA: $1.51 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.17x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-42.3%

-15.8%

-0.9%

YTD

-41.1%

-53.3%

Scan Membership

Breakout Watch

Latest: 2022-10-20

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 4 · Vol 0.17x

2026-10-21S2

Wk 4 · Vol 0.11x

2026-10-20S2

Wk 4 · Vol 0.12x

2026-10-19S2

Wk 4 · Vol 0.07x

2026-10-16S2

Wk 3 · Vol 0.17x

2026-10-15S2

Wk 3 · Vol 0.16x

2026-10-14S2

Wk 3 · Vol 0.24x

2026-10-13S2

Wk 3 · Vol 0.19x

2026-10-12S2

Wk 3 · Vol 0.17x

2026-10-09S2

Wk 2 · Vol 0.14x

2026-10-08S2

Wk 2 · Vol 0.07x

2026-10-07S2

Wk 2 · Vol 0.19x

Moving averages & range

50 DMA

$1.58

200 DMA

$1.51

52W High

$2.61

52W Low

$0.86

5D Low

$1.12

Resistance levels (recent highs)

20d High

$1.83

60d High

$1.94

120d High

$1.94

250d High

$2.61

Next resistance

+63.4%

to 20d High

ROE

-163.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Alzamend Neuro: quick answers

What stage is Alzamend Neuro in?

As of Oct 22, 2026, Alzamend Neuro (ALZN) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 28, 2026 and is in week 4. What the four stages mean

Is Alzamend Neuro in an uptrend?

Yes. Alzamend Neuro is in a Stage 2 uptrend. It trades 25.9% below its 200-day average, which is falling.

How far is Alzamend Neuro from its 52-week high?

Alzamend Neuro closed at $1.12 on Oct 22, 2026, 57.1% below its 52-week high of $2.61. Its 52-week low is $0.86.

How has Alzamend Neuro performed over the past year?

As of Oct 22, 2026, Alzamend Neuro is down 53.3% over the past year and down 41.1% so far in 2026.

Which sector and industry is Alzamend Neuro in?

Alzamend Neuro is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.